The U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted in favor of Pfizer Inc.'s (PFE) respiratory syncytial virus or RSV vaccine for older adults.
The Committee voted 7 to 4 on safety and 7 to 4 on effectiveness of RSV bivalent vaccine candidate PF-06928316 or RSVpreF, Pfizer said in a statement on Tuesday.
The vaccine candidate is currently under FDA review for the prevention of acute respiratory disease and lower respiratory tract disease caused by RSV in adults 60 years of age and older.
The FDA decision is expected by the Prescription Drug User Fee Act (PDUFA) goal date in May 2023.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.